Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BTIG analyst Mark Massaro downgrades Bionano Genomics (NASDAQ:BNGO) from Buy to Neutral.
Scotiabank analyst Sung Ji Nam downgrades Bionano Genomics (NASDAQ:BNGO) from Sector Outperform to Sector Perform and lowers...
Full year 2024 revenue guidance of $36.0 to $40.0 million; revenue for the third quarter of 2024 is expected to be $7.9 to 8.9 ...
Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0....
A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical School and Brigham and Women's Hospita...
Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the publication of the first multi-site study in multiple myeloma (MM) co...
A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Resear...
